Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Scancell Holdings PLC

SCLP.L ✓ COMPLIANT ☆ Track — members

LSE · Healthcare · Biotechnology & Medical Research ·

UK Micro Cap Analyst: STRONG BUY

Last Close

$0.13

▲ +0.10%

Market Cap $156.69M · Vol 791.04K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$156.69M

Micro Cap

Div Yield

N/A

Semi-annual dividend

EPS Growth

+0.80%

YoY

RSI (14)

50.94

Momentum

Beta

1.22

vs Market

52W High

$0.40

67.28% below

52W Low

$0.11

21.24% above

Volume

791.04K

Avg 4.51M

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

96.87%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Scancell Holdings PLC (SCLP.L) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does SCLP.L pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-1.95%

-3.43%

-57.51%

-23.67%

YTD

-3.43%

+6.22%

+11.28%

-56.03%

Financials & Valuation

TTM · Annual

Total Revenue	$6.28M
Net Income	$-16,353,727.00
Revenue Growth (YoY)	N/A
Gross Margin	94.95%
Operating Margin	-318.42%
Net Profit Margin	-260.50%
ROE	N/A
ROA · ROIC	-65.59% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	22.14
P/B	N/A
P/FCF	N/A
EPS Growth	+0.80%
Outstanding Shares	1.21B

Technical Indicators

50-Day SMA	$0.15
200-Day SMA	$0.18
RSI (14)	50.94
Beta	1.22
52-Week High	$0.40
52-Week Low	$0.11

Volume Today	791.04K
Avg Daily Volume (30D)	4.51M
Relative Volume	0.18x
Volatility (10D)	13.29
Volatility (30D)	19.46
Free Float	96.87%

Analyst Consensus

STRONG BUY

Current Price $0.13

Mean Target $0.34

52W Low$0.11 52W High$0.40

Current

Target

$0.11 $0.40

Current Analyst target

+162.75% upside potential · 3 analysts

Identifiers

ExchangeLSE

FIGIBBG001SBYQ98

ISINGB00B63D3314

CountryUnited Kingdom

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -2.54% RVMD Revolution Medicines Inc -0.40% ONC BeOne Medicines AG -1.22% 068270.KS Celltrion Inc +0.53% ABVX Abivax SA +0.66%

Company Profile

Scancell Holdings plc is a clinical-stage biopharmaceutical company. The Company is engaged in studying the human adaptive immune system, to generate medicines to treat unmet needs in cancer. The Company is building a pipeline of products by utilizing its four technology platforms: Moditope and ImmunoBody for vaccines and GlyMab and AvidiMab for antibodies. Its product pipeline includes Modi-1, Modi-2, SCIB1 & iSCIB1+, SCIB2, SC129, SC134, SC2811, SC27, and others. Modi-1 is the first therapeutic vaccine candidate from the Company’s Moditope platform, which targets citrullinated peptides from two different proteins which have been combined to reduce the possibility of tumor escape and have each been conjugated to a toll-like receptor (TLR) 1/2 agonist, which acts as an adjuvant. Modi-2, which targets homocitrullinated cancer antigens, is the second therapeutic vaccine candidate from the Company’s Moditope platform and has the potential to address different cancer indications to Modi-1.